The in vitro contracture test (IVCT) is the only available diagnostic method at present for evaluation of malignant hyperthermia (MH) susceptibility. However, the disadvantage of the IVCT is that it is invasive. Several studies suggest that an altered inositol phosphate system is involved in the development of MH. A greater concentration of inositol 1,4,5-trisphosphate (1,4,5-IP 3 ) was found in MH susceptible (MHS) than in normal (MHN) skeletal muscles. In this study the concentrations of 1,4,5-IP 3 in blood samples and skeletal muscle specimens of identical patients were measured in an attempt to define susceptibility to MH. Muscle biopsies were obtained from 34 patients with clinical suspicion of MH. Patients were first classified as MHS (n:19), MHN (n:8) or MH equivocal (MHE; n:7) by the standard IVCT. For detection of 1,4,5-IP 3 concentrations, blood samples were obtained and an additional muscle specimen was excised. After sample preparation, concentrations of 1,4,5-IP 3 were measured using radioimmunoassay. In blood samples, concentrations of 1,4,5-IP 3 were similar in all individuals tested for MH susceptibility and in control patients not tested for MH susceptibility (n:44). In skeletal muscle, 1,4,5-IP 3 concentrations were significantly higher in MHS than in MHE or MHN patients, respectively. Each MHS sample contained more 1,4,5-IP 3 than the highest concentration measured in MHN muscle. Defining arbitrary thresholds for 1,4,5-IP 3 concentration in skeletal muscles in order to discriminate between MHS and MHN status, it was possible to assign three MHE patients to MHS and four to MHN. This study supports the hypothesis that an altered inositol phosphate system might be involved in MH. However, measurement of 1,4,5-IP 3 concentration in a simple blood sample preparation is not reliable for MH susceptibility screening. (Br. J. Anaesth. 1997; 78: 541-547 3 4 Both caffeine and halothane produce abnormal contracture responses in muscle specimens obtained from MH susceptible (MHS) but not from normal (MHN) individuals. At present, the IVCT using caffeine and halothane is generally accepted as the "gold standard" for diagnosis of MH susceptibility. However, the major disadvantage of the IVCT is that it is invasive. Therefore, it would be desirable to have an accurate, non-invasive, low-cost screening test for MH susceptibility.
Summary
The in vitro contracture test (IVCT) is the only available diagnostic method at present for evaluation of malignant hyperthermia (MH) susceptibility. However, the disadvantage of the IVCT is that it is invasive. Several studies suggest that an altered inositol phosphate system is involved in the development of MH. A greater concentration of inositol 1,4,5-trisphosphate (1,4,5-IP 3 ) was found in MH susceptible (MHS) than in normal (MHN) skeletal muscles. In this study the concentrations of 1,4,5-IP 3 in blood samples and skeletal muscle specimens of identical patients were measured in an attempt to define susceptibility to MH. Muscle biopsies were obtained from 34 patients with clinical suspicion of MH. Patients were first classified as MHS (n: 19) , MHN (n:8) or MH equivocal (MHE; n:7) by the standard IVCT. For detection of 1,4,5-IP 3 concentrations, blood samples were obtained and an additional muscle specimen was excised. After sample preparation, concentrations of 1,4,5-IP 3 were measured using radioimmunoassay. In blood samples, concentrations of 1,4,5-IP 3 were similar in all individuals tested for MH susceptibility and in control patients not tested for MH susceptibility (n:44). In skeletal muscle, 1,4,5-IP 3 concentrations were significantly higher in MHS than in MHE or MHN patients, respectively. Each MHS sample contained more 1,4,5-IP 3 than the highest concentration measured in MHN muscle. Defining arbitrary thresholds for 1,4,5-IP 3 concentration in skeletal muscles in order to discriminate between MHS and MHN status, it was possible to assign three MHE patients to MHS and four to MHN. This study supports the hypothesis that an altered inositol phosphate system might be involved in MH. However, measurement of 1,4,5-IP 3 concentration in a simple blood sample preparation is not reliable for MH susceptibility screening. (Br. J. Anaesth. 1997; 78: 541-547).
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Susceptibility to malignant hyperthermia (MH) in
humans is diagnosed by in vitro contracture tests (IVCT) using halothane and caffeine on skeletal muscle specimens obtained at open biopsy. 1 2 In 1970 caffeine was introduced as the test drug for MH susceptibility followed by halothane 1 yr later. 3 4 Both caffeine and halothane produce abnormal contracture responses in muscle specimens obtained from MH susceptible (MHS) but not from normal (MHN) individuals. At present, the IVCT using caffeine and halothane is generally accepted as the "gold standard" for diagnosis of MH susceptibility. However, the major disadvantage of the IVCT is that it is invasive. Therefore, it would be desirable to have an accurate, non-invasive, low-cost screening test for MH susceptibility.
Skeletal muscle cells from MHS individuals have an inherited abnormality in the processes that are involved in the excitation-contraction coupling or myoplasmic calcium regulation, 5 6 leading to a rapid and sustained increase in myoplasmic calcium during anaesthetic-induced MH crisis. Intracellular calcium concentrations are controlled by different types of calcium release channels, that is the ryanodine receptor in the terminal cisternae of the sarcoplasmic reticulum (SR), the dihydropyridine receptor in the transverse tubule and the inositol-1,4,5-trisphosphate receptor. 6 7 In pigs, the defect predisposing to MH susceptibility is associated with the ryanodine receptor, possibly because of a specific breeding effect, 8 9 whereas the detailed molecular mechanisms leading to the human MH syndrome are still unknown. Recent studies indicated that a second factor or modulator is required for expression of the MH syndrome in humans. 10 Furthermore, dysfunction in the phosphoinositide pathway and metabolism of free fatty acids have been proposed as underlying causes of the alterations in calcium regulation in MH. [11] [12] [13] The second messenger inositol-1,4,5-trisphosphate (1,4,5-IP 3 ) has a key role in controlling both mobilization of calcium from internal stores and entry of external calcium.
14 As increased concentrations of 1,4,5-IP 3 were found in MHS individuals 12 and also in MHS swine, 11 there is an increasing number of reports indicating that an altered inositol phosphate system is involved in the development of MH. [15] [16] [17] [18] However, in skeletal muscle the sensitivity of the intracellular Ca 2; release mechanism to 1,4,5-IP 3 is highly dependent on experimental conditions, and this had led to conflicting views on the role of the phosphoinositide pathway in muscle. 19 In this study, we have measured basal concentrations of 1,4,5-IP 3 in blood samples and skeletal muscle specimens to determine if 1,4,5-IP 3 concentration in blood samples from patients with clinical suspicion of MH might be a reliable non-invasive screening test for MH classification. The second aim of this study was to see if a combination of a ryanodine contracture test and measurement of 1,4,5-IP 3 concentrations in skeletal muscle specimens could be helpful in assigning MHE patients to MHS and MHN groups. 25 .0; and glucose 11.1, and transported to our laboratory. Apart from these specimens, an additional muscle sample (weight 200-400 mg) was excised for measurement of 1,4,5-IP 3 concentration. Before cutting the fibres, the muscle specimen was clamped, and immediately after excision the samples were frozen in liquid nitrogen and stored at 980ЊC.
Patients and methods

IN VITRO CONTRACTURE TEST
The muscle bundles were dissected into 6-8 strips (length 15-25 mm; width 2-3 mm; weight 100-250 mg). All tests were performed within 5 h after biopsy. The muscle strips were suspended in an 80-ml organ bath perfused with Krebs-Ringer solution bubbled with carbogen continuously, temperature was kept constant at 37ЊC and pH was adjusted to 7.4. Isometric tension was amplified by a Gould THE (Cleveland, OH, USA) and recorded on a Gould polygraph TA 2000 (Cleveland, OH, USA) using a Fleck TF 3V force displacement transducer (Mainz, Germany). The muscles were stimulated electrically to achieve a supramaximal response by a Grass Stimulator SD 9 (Quincy, MA, USA) using a square wave with a duration of 1 ms and a frequency of 0.2 Hz. An initial baseline tension of 20 mN was applied. Two specimens were investigated simultaneously.
Patients Frozen muscle samples were powdered in a liquid nitrogen cooled dismembranator (Braun Melsungen, Germany) and the wet weight of the samples was measured. Subsequently, muscle and blood samples were mixed with 0.2 volume ice-cold 20% perchloric acid and kept on ice for 20 min. Proteins were sedimented by centrifugation at 2000 g for 15 min at 4ЊC. Supernatants were adjusted to a pH of 7.5 by addition of 10 N KOH and kept ice-cold. Precipitated KClO 4 was sedimented and removed by centrifugation. Samples were neutralized by adding 300 l of a 1:1 (v/v) of Freon (1,1,2-trichlorotrifluoroethane) and tri-n-octylamine, followed by vigorous mixing of the separate phases on a vortex mixer. After centrifugation for 1 min at 2000 g, three phases were obtained. A 400-l portion of the upper phase, which contained the neutralized sample, was removed for subsequent analysis. After addition of the assay buffer (D-myo-[ RYANODINE CONTRACTURE TEST After the IVCT, surplus muscle specimens were used in the ryanodine contracture test for diagnosis of MH susceptibility, as described recently. 20 Ryanodine was added as a bolus to the organ bath in order to obtain a concentration of 2 mol litre 91 . The development of contracture after ryanodine administration was characterized by attainment of three phases: (1) start of contracture (min); (2) In simple blood sample preparations, 1,4,5-IP 3 concentrations were similar in all individuals tested for MH susceptibility and in control patients ( fig. 1) . Concentrations of 1,4,5-IP 3 in the MHS group ranged from 4.3 to 11.6 (median 8.7) pmol/tube. In the MHE group, values were 5.1-12.5 (median 9.9) pmol/tube. Median 1,4,5-IP 3 concentrations in the MHN group (5.5 pmol/tube) were smaller than those in the other groups. However, the range (4.0-11.0 pmol/tube) did not differ significantly from concentrations in the MHS and MHE groups. The control population showed a homogeneous distribution with a minimum of 3.4 and a maximum of 12.0 pmol/tube, which were similar to the results of the MH patients.
In skeletal muscles from the same patients, there were significant differences in 1,4,5-IP 3 concentrations ( fig. 2) . The median in the MHS group (6.2 pmol/mg ww) was significantly higher than that in the MHN group (1.7 pmol/mg ww). The ranges in both groups also showed marked differences: 1,4,5 IP 3 -concentrations in the MHN group were 0.2-2.8 pmol/mg ww compared with 2.9-12.8 pmol/mg ww in the MHS group. Concentrations of 1,4,5-IP 3 in MHE individuals were between those of the MHS and MHN subjects, and were significantly different from the MHS results. Individual data for three MHE patients varied from 3.7 to 7.0 pmol/mg ww, corresponding to the range of values for MHS, and four values varied from 0.5 to 2.0 pmol/mg ww, corresponding to MHN. Individual data for contracture testing using ryanodine 2 mol litre 91 are presented in table 2. Contracture development after ryanodine administration was enhanced significantly in MHS compared with MHN muscles. Median values for MHE muscles were always between those of MHS and MHN. Table 3 summarizes the results of the IVCT, 1,4,5-IP 3 concentrations in skeletal muscle and the ryanodine contracture test in MHE patients. In an attempt to assign MHE muscles to either the MHS or MHN group, we arbitrarily denned thresholds for 1,4,5-IP 3 concentrations in skeletal muscles of ജ2.9 pmol/mg ww for MHS and ഛ2.8 pmol/mg ww for MHN. Thus an assignment of three MHE patients to the MHS group was possible. MHE patient Nos 1, 3, 6 and 7 were defined as MHN. Using the range of values for MHS and MHN according to the ryanodine contracture test, we arbitrarily denned intervals to categorize MHE muscles as either MHS or MHN, as described recently. 20 Three MHE muscles showed enhanced contracture development and were classified as MHS. In four muscles a marked delay in contracture development occurred and these were allocated to the MHN group. In five of seven MHE muscles, consistent results in both tests were observed. The same MH classification was possible using measurement of 1,4,5-IP 3 concentrations and ryanodine contracture testing.
Discussion
We have found that 1,4,5-IP 3 concentrations in skeletal muscle specimens were significantly higher in MHS than in MHN patients. In contrast, 1,4,5-IP 3 concentrations in blood samples of the same patients and controls did not differ. Thus it was possible to differentiate between MHS and MHN individuals by measurement of 1,4,5-IP 3 concentrations in skeletal muscle specimens but not in simple blood sample preparations. Furthermore, we have demonstrated that a combination of a ryanodine contracture test and measurement of 1,4,5-IP 3 concentrations in skeletal muscle specimens could be helpful in assigning MHE patients to MHS and MHN groups. For evaluation of susceptibility to MH, only the in vitro contracture tests with halothane and caffeine have been shown to be reliable in distinguishing between MHS and MHN individuals. Human skeletal muscle contracture testing for diagnosis of MH susceptibility seems to be highly sensitive. 22 However, the specificity of the IVCT was estimated as 80-85%. 23 For the first time in 1993 four cases were described of presumably false-negative contracture responses in muscle specimens from patients with a clinical history of MH. 24 However, there is considerable debate about these cases because the authors did not use the EMHG test procedure; in two cases there was no clinical evidence of MH and muscle histology and neurological examination were not performed in all patients. Four additional cases were presented recently of false-negative IVCT results in juvenile patients surviving MH episodes during general anaesthesia. 25 The authors suggested that the age of the patients might have affected the contracture results. However, whereas in newborn MHS piglets decreased responsiveness to halothane compared with mature animals has been observed, 26 age dependence of MH in humans has not been demonstrated until now.
The caffeine contracture test produces falsenegative results in approximately 15% of MH susceptible patients. Moreover, both caffeine and the halothane tests were shown not to be specific for MH, as positive IVCT results were observed in some individuals with other muscle disorders. 27 Contracture test results in control patients suggested a false-positive rate of approximately 4% using the European 28 and 9% using the North American MH procedures. 23 The hypothesis that MH is caused by an abnormal ryanodine receptor gene focused interest on developing an alternative test for diagnosis of MH using ryanodine. In vitro studies of ryanodine-induced contractures showed that in muscle specimens of MHS patients, contractures developed significantly earlier than in specimens from MHN individuals. 20 29-32 Although the results of contracture testing with ryanodine in conjunction with the standard halothane and caffeine contracture tests could improve diagnosis of MH susceptibility, 33 the ryanodine contracture test is also not specific for MH. Moreover, the disadvantage of contracture testing with halothane, caffeine and ryanodine is that it is invasive, time consuming and expensive.
Since the identification of the ryanodine receptor gene, thought to be responsible for MH, 34 35 it has been assumed that MH susceptibility could be detected using a genetic test based on DNA analysis. Molecular genetic studies have shown that a single point mutation in the ryanodine receptor gene (C1843-T mutation) is frequently correlated with MH in swine. 9 However, the corresponding mutation in the human genom (C1840-T mutation) was detected first in only one of 35 MH families. 36 At present, the frequency of this single point mutation in the human ryanodine receptor gene has been calculated to be less than 10%. 10 37 Moreover, mutation screening of the ryanodine receptor gene in MHS individuals has led to the identification of seven other mutations to date. 38 Furthermore, genetic heterogeneity has been reported in MH 39 and several additional MHS loci on chromosomes 17, 7 and 3.
40-42 DNA-based testing in MH would be non-invasive, accurate and less expensive, but there is little probability that a universal genetic test for MH susceptibility in humans will be easily developed because of heterogeneity, increasing number of identified mutations in MH and association with muscle cell deficiencies induced by other neuromuscular diseases.
Activation of G protein-linked receptors led to the dissociation of the G protein in the subunits G ␣ and G ␤␥ , both of which can activate different phospholipase C (PLC) enzymes. 14 In energy-requiring transducing mechanisms, PLC hydrolyses the lipid precursor phosphatidylinositol 4,5-bisphosphate to stimulate formation of both diacylglycerol (DAG) and 1,4,5-IP 3 , which binds to an 1,4,5-IP 3 receptor to mobilize stored Ca 2; . It is believed that abnormal regulation of intracellular Ca 2; concentration within skeletal muscle is the process of primary significance in MH episodes. Furthermore, malfunctions in the phosphoinositide cycle and free fatty acid metabolism were shown to be associated with MH susceptible muscle. 11-13 16-18 Basal concentrations of 1,4,5-IP 3 in skeletal muscles of MHS swine 11 and humans 12 were found to be significantly higher than in MHN. It was demonstrated that successive additions of 1,4,5-IP 3 induced short pulses of calcium release. 43 Moreover, microinjection of 1,4,5-IP 3 increased intracellular Ca 2; in intact skeletal muscle from MHS swine with higher potency and efficacy than in muscles from MHN swine. 15 Dantrolene decreased resting intracellular Ca 2; concentration and prevented l,4,5-IP 3 -induced increase in intracellular Ca 2;
. These results suggest that skeletal muscle fibres from MHS have a higher sensitivity to l,4,5-IP 3 -induced regulation of intracellular Ca 2; , which could play an important role in MH induction. In the presence of halothane, l,4,5-IP 3 -concentration increased to a higher extent in MHS than in MHN muscles. 11 Moreover, it has been shown that halothane challenge caused an increase in the second messengers 1,4,5-IP 3 and 1,3,4,5-IP 4 in MHS but not in MHN swine. 18 Treatment with dantrolene reduced the increase to values close to basal concentrations. To date, it is not clear if the alterations in phosphoinositide metabolism are primary in MH induction or of a secondary nature. ATP at low concentrations enhances the ability of l,4,5-IP 3 to open Ca 2; channels in the SR membrane. It has been hypothesized that the lower the ATP concentration, possibly as a result of the hypermetabolic state of MH, and the higher the 1,4,5-IP 3 concentration, the more Ca 2; is released. 17 It has been speculated therefore that measurement of Ca 2; or 1,4,5-IP 3 concentrations, or both, in muscle but also in nonmuscle cells, could be used for diagnosing MH susceptibility. [44] [45] [46] However, the differences in these investigations were not reliable in determining susceptibility to MH until now. 46 Moreover, in accordance with our data from simple blood sample preparations, no differences in 1,4,5-IP 3 concentrations in human red blood cells were observed between MHS and MHN. 47 In summary, this study supports the hypothesis that an altered inositol phosphate system might be involved in MH. One might speculate that the differences between skeletal muscles might also exist in other cell types, including blood cells. Further investigations are required to develop an accurate, reliable, low-cost and non-invasive screening test. Such a test might be measurement of 1,4,5-IP 3 concentration in different blood components or cell types, or methods of detecting genetic defects in 1,4,5-IP 3 metabolism.
